Guerbet USA, the U.S. affiliate of contrast developer Guerbet, has formed a commercial partnership with radiation dose-tracking software developer Imalogix.
Guerbet will offer the artificial intelligence-based Imalogix platform, which features a self-learning neural network that enables organizations to understand and benchmark best practices for radiation dose management of diagnostic imaging and interventional procedures, according to the company. Using the deep-learning software recommendations, institutions can proactively change behavior down to the scanner, protocol, and operator level, Guerbet said.
